Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 10/20 | 0.47 |
| ▸ | UBE2M | P61081 | 8/20 | 0.46 |
| ▸ | DCUN1D1 | Q96GG9 | 8/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3765384 | 0.79 | HPGD (0.48) | CACNA1BUBE2MDCUN1D1NR1I2GAA | |
| SCHEMBL13002406 | 0.78 | CACNA1B (0.51) | CACNA1BUBE2MDCUN1D1NR1I2GAA | |
| SCHEMBL13291497 | 0.78 | CACNA1B (0.49) | CACNA1BNR1I2GAALMNASMN1; SMN2 | |
| SCHEMBL8083318 | 0.78 | CACNA1B (0.46) | CACNA1BUBE2MDCUN1D1NR1I2GAA | |
| SCHEMBL3485872 | 0.77 | CACNA1B (0.47) | CACNA1BUBE2MDCUN1D1NR1I2GAA | |
| SCHEMBL8236293 | 0.77 | CACNA1B (0.51) | CACNA1BNR1I2GAACYP3A4HPGD | |
| SCHEMBL3485159 | 0.77 | CACNA1B (0.50) | CACNA1BNR1I2GAACYP3A4HPGD | |
| SCHEMBL3486594 | 0.77 | CACNA1B (0.53) | CACNA1BNR1I2CYP3A4 | |
| SCHEMBL13543317 | 0.77 | GAA (0.50) | CACNA1BNR1I2GAACYP3A4HPGD | |
| SCHEMBL8240680 | 0.76 | STS (0.53) | CACNA1BNR1I2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765736-B2 | Benzenesulfonamide compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2014-07-01 | — | — | US | claimed |
| US-20100311792-A1 | Benzenesulfonamide Compounds and the Use Thereof | PURDUE PHARMA L.P. | 2010-12-09 | — | — | US | claimed |
| WO-2009040659-A2 | BENZENESULFONAMIDE COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. (DE) | 2009-04-02 | — | — | WO | claimed |
| US-8765736-B2 | Benzenesulfonamide compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20100311792-A1 | Benzenesulfonamide Compounds and the Use Thereof | PURDUE PHARMA L.P. | 2010-12-09 | — | — | US | disclosed |
| WO-2009040659-A2 | BENZENESULFONAMIDE COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. (DE) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311792-A1 | Benzenesulfonamide Compounds and the Use Thereof | CACNA1A, CACNA1E, CACNA1B | CACNA1B 3/4885UBE2M 4052/4885DCUN1D1 3305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.